📰 Late Breaking News
Late Breaking News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Late Breaking. Real-time updates on events, politics, business and more.
April 20, 2024
Hundreds of anglers participated in the Castin' 'n Catchin' tournament in Scottsboro, Alabama, with the aim of raising funds for children suffering from heart issues.
March 11, 2024
ROOT, Switzerland--(BUSINESS WIRE)--Mar 11, 2024--
March 10, 2024
Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
November 15, 2023
This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.
November 10, 2023
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due...
November 4, 2023
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs
November 3, 2023
November 16 Event to feature KOL perspective on Emerging HBV TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on...
October 2, 2023
–– Late-breaking results from Phase III trial of Ocrevus subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis will be presented –– 10-year Ocrevus...
October 2, 2023
–– Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented–– 10-year Ocrevus efficacy and safety data show significant benefit in slowing long-term disability progression and consistent lo...